Immunology
Effects of TCR activation on naive cord blood T cells characterized
Published in Blood Weekly, February 12th, 2004
UCB "is now being considered an alternative to bone marrow for restoring hematopoiesis after myeloablative therapy," scientists in Spain noted. "The lower risk of acute and chronic graft-versus-host disease in patients who received UCB cells seems related to the nature of UCB-T cells."
"Phenotypically, UCB-CD3+ cells are mostly naive (CD45RA+) and represent a transitional population between thymocytes and adult T cells," explained E. Canto and colleagues at Sant Pau Hospital in Barcelona, who "examined the immune reactivity of highly purified, negatively selected...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2004-02-12)
More Articles from Blood Weekly
- Stem-Cell Transplantation
Risedronate prevents bone loss in allo-SCT survivors - Bloodstream Infections
Once-weekly Dalbavancin shows superiority for bloodstream infections in study - Bone Fractures
Bone graft clinical trial initiated at lead U.S. site - Bone Grafts
Further studies of transplanted composite bone grafts-implants are needed - Bone Marrow Transplant
Researchers discover secret for recalling stem cells - Cancer Incidence
Exposure to high levels of trichloroethylene may be increase risk of NHL - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
